Darolutamide has proved it has cancer cell killing potential by showing lethal reduction of cell proliferation in different cell lines obtained from mCRPC patients including AR mutants and prominent inhibition of tumor cell burden and number in xenograft mouse models as compared to second-generation antiandrogen agents (Shore, 2017). The gene discussed is AR; the disease is neoplasm.